Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Aripiprazole Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy PG173

    Aripiprazole Oral Disintegrating Tablet, Solution, and Oral Film Coverage

    Customize your policy alerts

    Sign up for Oscar Health Policy PG173 alerts

    Get alerted when Policy PG173 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical medical-necessity and prior-authorization criteria for aripiprazole oral disintegrating tablets, oral solution, and specified oral films for covered psychiatric and neurologic indications.

    Policy Summary
    PayerOscar Health
    PolicyAripiprazole Oral Disintegrating Tablet, Solution, and Oral Film Coverage
    Policy CodePolicy PG173
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of the applicable diagnosis, formulation requirements, dosing, age, and prior-treatment criteria with the authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30 mg/dayMaximum daily dose
    6Minimum age for selected indications
    13 yearsMinimum age for schizophrenia
    LifetimeMaximum off-label authorization duration
    5

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Named indication groups

    Covered Indications and Exclusions

    General Medical Necessity

    Covered when ALL general medical-necessity criteria are met.

    General medical necessity

    • Documentation indicates the member is unable or unwilling to take the tablet form.
    • If the request is for Mezofy or Opipza oral film, the member is unable to use or has tried and failed aripiprazole tablet/ODT.
    • Aripiprazole oral disintegrating tablet, solution, or film is prescribed at a dose and frequency within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the requested indication.Maximum 30 mg/day

      The policy references once-daily dosing and a maximum daily dose of 30 mg/day.

    • The member meets the applicable indication-specific criteria.

    Adjunctive Therapy of Major Depressive Disorder

    Covered when ALL criteria are met.

    Adjunctive therapy of major depressive disorder

    • The request is for Abilify oral disintegrating tablet or solution or Opipza oral film.
    • The member is 18 years of age or older.Age 18 years or older
    • The member has a diagnosis of major depressive disorder.

    Bipolar Disorder

    Covered when ALL criteria are met.

    Bipolar disorder

    • The request is for Abilify oral disintegrating tablet or solution.
    • The member is 10 years of age or older.Age 10 years or older
    • The member has a diagnosis of bipolar disorder.

    Irritability Associated with Autistic Disorder

    Covered when ALL criteria are met.

    Irritability associated with autistic disorder

    • The request is for Abilify oral disintegrating tablet or solution or Opipza oral film.
    • The member is between 6 and 17 years of age.Age 6 through 17 years
    • The member has a diagnosis of irritability associated with autistic disorder, including aggression, deliberate self-injurious behavior, temper tantrums, or quickly changing moods.

    Postpartum Psychosis

    Covered when ALL criteria are met, including ONE qualifying psychosis presentation.

    Postpartum psychosis

    • The request is for Abilify oral disintegrating tablet or solution.
    • The medication is prescribed by or in consultation with a psychiatrist.
    • ONE qualifying psychosis presentation

      • New-onset psychotic symptoms in the postpartum period, such as delusions, disorganized thoughts, hallucinations, agitation, or bizarre behavior.
      • Bipolar disorder with postpartum psychotic symptoms.
      • A primary mental disorder with psychotic symptoms during the peripartum period.

    Schizophrenia

    Covered when ALL criteria are met.

    • The request is for Abilify oral disintegrating tablet or solution or Mezofy or Opipza oral film.
    • The member is 13 years of age or older.Age 13 years or older
    • The member has a diagnosis of schizophrenia.

    Tourette Syndrome or Chronic Tic Disorders

    Covered when ALL criteria are met.

    Tourette syndrome or chronic tic disorders

    • The request is for Abilify oral disintegrating tablet or solution or Opipza oral film.
    • The member is 6 years of age or older.Age 6 years or older
    • The member has a diagnosis of Tourette disorder or chronic tic disorders.

    Specified Off-Label Uses

    Covered when ALL criteria are met for ONE listed off-label use.

    Specified off-label uses

    • The request is for Abilify oral disintegrating tablet or solution or Mezofy or Opipza oral film.
    • The member is 18 years of age or older.Age 18 years or older
    • ONE eligible off-label use

      • Agitation or aggression associated with psychiatric conditions, substance intoxication, or other organic causes.
      • Agitation/aggression and psychosis related to dementia when symptoms are dangerous, severe, or cause significant patient distress.

    Aripiprazole oral disintegrating tablet or solution for any indication or use other than the covered criteria is excluded as experimental, investigational, or unproven and is not medically necessary.

    The policy specifically identifies ADHD, chronic lower back pain, eating disorders including anorexia nervosa, generalized anxiety disorder or panic disorder, and postpartum depression as non-covered uses because high-quality evidence supporting the safety and efficacy of aripiprazole for these indications is lacking.

    Prior Authorization and Documentation Requirements

    Prior Authorization

    General Prior Authorization Requirements

    Prior authorization is required for aripiprazole (Abilify) oral disintegrating tablet or solution and Mezofy/Opipza aripiprazole oral film. The request must document the requested product or formulation, applicable age and diagnosis, dosing, and indication-specific medical-necessity criteria.

    • The member is unable or unwilling to take the tablet form.
    • For Mezofy/Opipza oral film, the member is unable to use or has tried and failed aripiprazole TBDP/ODT.
    • The prescribed dose and frequency must be once daily, up to a maximum of 30 mg/day, and within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the requested indication.
    • The member must meet the applicable indication-specific criteria, including product/formulation, minimum or applicable age, and diagnosis requirements for major depressive disorder, bipolar disorder, irritability associated with autistic disorder, postpartum psychosis, schizophrenia, Tourette disorder or chronic tic disorders, or an eligible off-label use.
    Prior Authorization

    Off-Label Authorization Duration

    Clinical Background

    Aripiprazole is an atypical, second-generation antipsychotic and dopamine-system stabilizer. It acts as a partial dopamine agonist and has affinity for serotonin 5-HT1A and 5-HT2A receptors. This policy addresses oral disintegrating tablet, oral solution, and specified oral-film formulations used in mood, psychotic, developmental, and tic-related disorders. Important safety concerns include increased mortality in older adults with dementia, increased suicidal ideation in pediatric and young adult patients, and metabolic effects such as hyperlipidemia, hyperglycemia, and weight gain.

    Policy Definitions

    Adjunctive therapy
    DefinitionUse of a medication in combination with another medication.
    PurposeOften used to enhance the main therapy or treat additional symptoms.
    Policy exampleAripiprazole is approved as adjunctive therapy for major depressive disorder.
    Atypical antipsychotics
    DefinitionA group of antipsychotic drugs used to treat psychiatric conditions.
    Movement-disorder riskGenerally less likely to produce extrapyramidal side effects, or movement disorders, than older typical antipsychotics.
    Clinical category

    Initial Approval Criteria

    Adjunctive Major Depressive Disorder Therapy

    Initial approval requires ALL criteria.

    Major depressive disorder

    • The request is for Abilify oral disintegrating tablet or solution or Opipza oral film.
    • The member is 18 years of age or older.Age 18 years or older
    • The member has a diagnosis of major depressive disorder.

    Bipolar Disorder

    Initial approval requires ALL criteria.

    Bipolar disorder

    Continuation and Authorization Duration

    Off-Label Authorization Duration

    If the specified off-label prior-authorization criteria are met, authorization may continue for up to a lifetime.

    Continuation duration for qualifying off-label use

    • The applicable off-label prior-authorization criteria have been met.Authorization up to lifetime

      The policy states the duration but does not provide separate clinical continuation criteria.

    Required Prior Therapy and Alternatives

    StepRequest or indicationRequired step-therapy historyCoverage
    1Mezofy or Opipza oral filmMember is unable to use, or has tried and failed, aripiprazole tablet or ODTCovered when required criteria are met
    StepRequest or indicationRequired step-therapy historyCoverage
    1Delusional infestation (delusional parasitosis)Member is unable to use, or has tried and failed, both olanzapine and risperidoneCovered when required criteria are met
    StepRequest or indicationRequired step-therapy historyCoverage
    1Treatment-resistant obsessive-compulsive disorder (OCD)Partial response to initial treatment, such as clomipramine, fluvoxamine, fluoxetine, paroxetine, or sertralineCovered when required criteria are met

    Product and Dose Limits

    Maximum daily dose
    Covered productsAripiprazole oral disintegrating tablet, oral solution, or oral film.
    Maximum daily dose30 mg/day.
    Dosing requirementThe prescribed dose and frequency must be within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the requested indication.
    Policy Summary
    PayerOscar Health
    PolicyAripiprazole Oral Disintegrating Tablet, Solution, and Oral Film Coverage
    Policy CodePolicy PG173
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of the applicable diagnosis, formulation requirements, dosing, age, and prior-treatment criteria with the authorization request.
    SourceLink
    On This Page
    Covered Indications and ExclusionsPrior Authorization and Documentation RequirementsClinical BackgroundPolicy DefinitionsInitial Approval CriteriaContinuation and Authorization DurationRequired Prior Therapy and AlternativesProduct and Dose Limits
    Delusion disorder.
  1. Huntington disease-associated chorea.
  2. Delusional infestation, with inability to use or prior trial and failure of olanzapine and risperidone.
  3. Treatment-resistant obsessive-compulsive disorder in a member with a partial response to initial treatment, such as clomipramine, fluvoxamine, fluoxetine, paroxetine, or sertraline.
  4. When the applicable prior-authorization criteria are met, an eligible off-label aripiprazole request may be authorized for up to a lifetime.

    • This duration applies to qualifying off-label uses under the policy, including eligible agitation or aggression, severe behavioral or psychological symptoms of dementia, delusion disorder, Huntington disease-associated chorea, delusional infestation, and treatment-resistant OCD.
    Step Therapy

    Delusional Infestation Alternatives

    For delusional infestation (also called delusional parasitosis), document that the member is unable to use or has tried and failed both specified alternatives.

    • Required alternatives: olanzapine and risperidone.
    Step Therapy

    Treatment-Resistant OCD Prior Therapy

    For treatment-resistant obsessive-compulsive disorder, document that the member has had a partial response to initial treatment and provide the qualifying treatment history.

    • Initial treatment may include antidepressants such as clomipramine, fluvoxamine, fluoxetine, paroxetine, or sertraline.
    • The request must be for a member age 18 or older and for an eligible off-label use.
    Documentation Required

    Clinical Diagnosis and Formulation Documentation

    Submit current clinical documentation supporting the diagnosis, requested formulation, and medical-necessity rationale. Documentation includes written information sufficient to substantiate the clinical facts underlying the request.

    • Provide up-to-date chart notes, relevant test results, and/or relevant imaging reports supporting the diagnosis.
    • Document the member's diagnosis and the requested product and formulation, including why the tablet form cannot or will not be used when applicable.
    • Document the indication-specific rationale and the prescribed dose and frequency, including support for dosing outside FDA labeling when relying on compendia or evidence-based published guidelines.
    • For postpartum psychosis, document that the medication is prescribed by or in consultation with a psychiatrist and provide evidence of new-onset postpartum psychotic symptoms, bipolar disorder with postpartum psychotic symptoms, or a primary mental disorder with psychotic symptoms during the peripartum period.
    Documentation Required

    Prior Treatment and Alternative Failure Documentation

    Document prior treatment and alternative failure whenever required by the requested product or indication. Prescription claims records and/or prescription receipts may be used to support prior trials of formulary alternatives.

    • For Mezofy/Opipza oral film, document inability to use or failure of aripiprazole TBDP/ODT.
    • For delusional infestation, document inability to use or failure of olanzapine and risperidone.
    • For treatment-resistant OCD, document partial response to qualifying initial antidepressant treatment, such as clomipramine, fluvoxamine, fluoxetine, paroxetine, or sertraline.
    Documentation Required

    Postpartum Psychosis Documentation

    For postpartum psychosis requests, the prescriber must be a psychiatrist or the medication must be prescribed in consultation with a psychiatrist. Supporting clinical evidence must establish postpartum or peripartum psychosis.

    • Acceptable evidence includes new-onset psychotic symptoms such as delusions, disorganized thoughts, hallucinations, agitation, or bizarre behavior during the postpartum period.
    • Evidence may also include bipolar disorder with postpartum psychotic symptoms or a primary mental disorder with psychotic symptoms during the peripartum period.
    Denial Risk

    Failure to Meet General Medical-Necessity Criteria

    The request is at risk for denial if any general medical-necessity requirement is not met or adequately documented. The Plan requires all applicable criteria to be satisfied.

    • No documentation that the member is unable or unwilling to take the tablet form.
    • For oral film, no documented inability to use or failure of aripiprazole TBDP/ODT.
    • Dose or frequency exceeds once daily or 30 mg/day without support from compendia or evidence-based published dosing guidelines.
    • The requested product, member age, diagnosis, or indication does not meet the applicable indication-specific criteria.
    • Required clinical notes, test results, imaging, diagnosis, formulation rationale, or prior-treatment records are missing or insufficient.
    Denial Risk

    Unlisted or Unsupported Indication

    Aripiprazole for an indication not supported by the policy is considered not medically necessary because it is experimental, investigational, or unproven. Requests for unlisted or unsupported uses are subject to denial.

    • The policy statement specifically addresses aripiprazole oral disintegrating tablet or solution for any other indication or use; the listed eligible indications and qualifying off-label uses must be followed.
    • Provide evidence and documentation that the request fits an eligible indication; otherwise, the request may be denied as experimental, investigational, or unproven.
    Denial Risk

    Specified Non-Covered Uses

    The following uses are identified as non-covered because available evidence does not establish safety and efficacy for the requested use. Requests for these indications are subject to denial as experimental, investigational, or not medically necessary.

    • Attention Deficit Hyperactivity Disorder (ADHD).
    • Chronic Lower Back Pain (CLBP).
    • Eating disorders, including anorexia nervosa (AN).
    • Generalized Anxiety Disorder (GAD) or panic disorder.
    • Postpartum depression.
    Antipsychotic medication class.
    Boxed warning
    DefinitionThe most serious type of warning issued by the Food and Drug Administration.
    Alternative nameAlso known as a black box warning.
    PurposePlaced on prescription-drug labeling when serious or life-threatening risks exist.
    Irritability associated with autistic disorder
    DefinitionIrritability associated with autism spectrum disorder.
    Behavioral manifestationsMay manifest as aggression or deliberate self-injurious behavior.
    Additional manifestationsMay include temper tantrums or quickly changing moods.
    Postpartum psychosis
    DefinitionA rare but serious mental-health emergency.
    TimingCharacterized by sudden onset of psychotic symptoms shortly after childbirth.
    SymptomsOften characterized by acute-onset delusions, disorganized thoughts, hallucinations, and/or agitation.
    Schizophrenia
    DefinitionA chronic and severe mental disorder characterized by disruptions in thinking, perception, emotions, and behavior.
    Common symptomsHallucinations and delusions are common.
    Clinical categorySevere, chronic mental disorder.
    Tourette's syndrome
    DefinitionA neurological disorder characterized by sudden, repetitive, rapid, and unwanted movements or vocal sounds.
    Characteristic symptomsThe movements or vocal sounds are called tics.
    Clinical categoryNeurological tic disorder.
  5. The request is for Abilify oral disintegrating tablet or solution.
  6. The member is 10 years of age or older.Age 10 years or older
  7. The member has a diagnosis of bipolar disorder.
  8. Irritability Associated with Autistic Disorder

    Initial approval requires ALL criteria.

    Irritability associated with autistic disorder

    • The request is for Abilify oral disintegrating tablet or solution or Opipza oral film.
    • The member is between 6 and 17 years of age.Age 6 through 17 years
    • The member has a diagnosis of irritability associated with autistic disorder.

    Postpartum Psychosis

    Initial approval requires ALL criteria and ONE qualifying psychosis presentation.

    Postpartum psychosis

    • The request is for Abilify oral disintegrating tablet or solution.
    • The medication is prescribed by or in consultation with a psychiatrist.
    • ONE qualifying psychosis presentation

      • New-onset psychotic symptoms in the postpartum period.
      • Bipolar disorder with postpartum psychotic symptoms.
      • A primary mental disorder with psychotic symptoms during the peripartum period.

    Schizophrenia

    Initial approval requires ALL criteria.

    • The request is for Abilify oral disintegrating tablet or solution or Mezofy or Opipza oral film.
    • The member is 13 years of age or older.Age 13 years or older
    • The member has a diagnosis of schizophrenia.

    Tourette Syndrome or Chronic Tic Disorders

    Initial approval requires ALL criteria.

    Tourette syndrome or chronic tic disorders

    • The request is for Abilify oral disintegrating tablet or solution or Opipza oral film.
    • The member is 6 years of age or older.Age 6 years or older
    • The member has a diagnosis of Tourette disorder or chronic tic disorders.

    Specified Off-Label Uses

    Initial approval requires ALL criteria and ONE eligible off-label use.

    Specified off-label use

    • The request is for Abilify oral disintegrating tablet or solution or Mezofy or Opipza oral film.
    • The member is 18 years of age or older.Age 18 years or older
    • ONE eligible off-label use

      • Agitation or aggression associated with psychiatric conditions, substance intoxication, or other organic causes.
      • Agitation/aggression and psychosis related to dementia when symptoms are dangerous, severe, or cause significant patient distress.
      • Delusion disorder.
      • Huntington disease-associated chorea.
      • Delusional infestation, with inability to use or prior trial and failure of olanzapine and risperidone.
      • Treatment-resistant obsessive-compulsive disorder with a partial response to initial treatment, such as clomipramine, fluvoxamine, fluoxetine, paroxetine, or sertraline.